http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2728589-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd960f49b1d436476fcc80eac8ff0662 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2019-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77aa10f5340ece3935a85dbc4d12f029 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3576c6cd99c30f5e7bc56866afe72a63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_259ef264d5f0a4cd073defe756b9ba5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7201c305d868510ca5681ad40576d30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee99b663122d724dbae1f723afadc9fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f4053c5219765ef321e6824151936c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19605e4c5f9086a88f36740c0fbe242d |
| publicationDate | 2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2728589-C1 |
| titleOfInvention | Method for aetiological verification of cytomegaloviral pneumonia in hiv-infected patients |
| abstract | FIELD: biotechnology.SUBSTANCE: invention refers to biotechnology, particularly to diagnosing infectious diseases. Method involves examining a specific set of biological material of patients, such as blood and respiratory tract samples: BAL, bronchial biopsy material and sputum. Detecting CMV DNA in a blood sample selected from whole blood in a concentration of not more than 1.0 lg copies in 10leukocytes or blood plasma, as well as BAL sample – in concentration of not more than 400 copies/ml and/or bronchial biopsy material – not more than 400 copies/10cells and/or sputum – not more than 3,500 copies/ml with 90 % probability excludes the presence of CMV-pneumonia and enables to conclude on the presence of lung involvement of other aetiology.EFFECT: invention can be used for specification of aetiology of lung pathology in HIV-infected patients, particularly elimination or confirmation of pneumonia of cytomegalovirus nature (cytomegalovirus pneumonia, CMV-pneumonia).1 cl, 2 dwg, 2 tbl, 2 ex |
| priorityDate | 2019-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.